IT1290781B1 - ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES. - Google Patents

ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.

Info

Publication number
IT1290781B1
IT1290781B1 IT96RM000364A ITRM960364A IT1290781B1 IT 1290781 B1 IT1290781 B1 IT 1290781B1 IT 96RM000364 A IT96RM000364 A IT 96RM000364A IT RM960364 A ITRM960364 A IT RM960364A IT 1290781 B1 IT1290781 B1 IT 1290781B1
Authority
IT
Italy
Prior art keywords
treatment
therapeutic agent
degenerative diseases
active therapeutic
neuronal degenerative
Prior art date
Application number
IT96RM000364A
Other languages
Italian (it)
Inventor
Cinzia Piazza
Vincenzo Politi
Mario Materazzi
Original Assignee
Polifarma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma Spa filed Critical Polifarma Spa
Publication of ITRM960364A0 publication Critical patent/ITRM960364A0/en
Priority to IT96RM000364A priority Critical patent/IT1290781B1/en
Priority to CA002255748A priority patent/CA2255748C/en
Priority to JP54197097A priority patent/JP3725172B2/en
Priority to HU0000124A priority patent/HUP0000124A3/en
Priority to EP97925266A priority patent/EP0914131A1/en
Priority to BR9709379-3A priority patent/BR9709379A/en
Priority to AU30468/97A priority patent/AU3046897A/en
Priority to PCT/IT1997/000117 priority patent/WO1997045127A1/en
Publication of ITRM960364A1 publication Critical patent/ITRM960364A1/en
Application granted granted Critical
Publication of IT1290781B1 publication Critical patent/IT1290781B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
IT96RM000364A 1996-05-28 1996-05-28 ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES. IT1290781B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT96RM000364A IT1290781B1 (en) 1996-05-28 1996-05-28 ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
EP97925266A EP0914131A1 (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
JP54197097A JP3725172B2 (en) 1996-05-28 1997-05-23 A therapeutic agent active in the treatment of neurodegenerative diseases comprising uridine
HU0000124A HUP0000124A3 (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
CA002255748A CA2255748C (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
BR9709379-3A BR9709379A (en) 1996-05-28 1997-05-23 Use of uridine, and, composition for the treatment of disorders of the nervous system due to the selective degeneration of neuronal or glial cells in mammals.
AU30468/97A AU3046897A (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
PCT/IT1997/000117 WO1997045127A1 (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96RM000364A IT1290781B1 (en) 1996-05-28 1996-05-28 ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
US1854396P 1996-05-29 1996-05-29

Publications (3)

Publication Number Publication Date
ITRM960364A0 ITRM960364A0 (en) 1996-05-28
ITRM960364A1 ITRM960364A1 (en) 1997-11-28
IT1290781B1 true IT1290781B1 (en) 1998-12-10

Family

ID=26332100

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96RM000364A IT1290781B1 (en) 1996-05-28 1996-05-28 ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.

Country Status (4)

Country Link
EP (1) EP0914131A1 (en)
AU (1) AU3046897A (en)
IT (1) IT1290781B1 (en)
WO (1) WO1997045127A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
DK2329829T3 (en) * 1998-07-31 2014-07-21 Massachusetts Inst Technology Utilization of uridine in combination with choline for the treatment of neurological disorders
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
PL209031B1 (en) * 2001-04-30 2011-07-29 Trommsdorff Arzneimittel Pharmaceutically active uridine esters
US6767202B2 (en) 2001-12-18 2004-07-27 3M Innovative Properties Company Tooling with helical coils for structured surface articles
CA2566612C (en) 2004-05-13 2015-06-30 Massachusetts Institute Of Technology Uridine effects on dopamine release
WO2006031683A2 (en) * 2004-09-15 2006-03-23 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
US8318798B2 (en) 2005-11-24 2012-11-27 National University Corporation Hokkaldo University Therapeutic agent for neurodegenerative disease
WO2009059306A1 (en) 2007-11-02 2009-05-07 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1178044B (en) * 1984-10-09 1987-09-03 Polifarma Spa PHARMACEUTICAL ACTIVE AGENT FOR THE TREATMENT OF CEREBRAL DISEASES BASED ON URIDINE
IT1219667B (en) * 1988-06-21 1990-05-24 Polifarma Spa USE OF URIDINE IN THE PHARMACOLOGICAL TREATMENT OF DISORDERS DUE TO ALTERATED DOPAMINERGIC BALANCE
IT1241984B (en) * 1990-06-13 1994-02-02 Polifarma Spa USE OF URIDINE IN THE PHARMACOLOGICAL TREATMENT OF PERIPHERAL COMPLICATIONS OF DIABETES
JPH05304951A (en) * 1992-04-06 1993-11-19 N T Sci:Kk Culture solution for early embryo and embryonic stem cell

Also Published As

Publication number Publication date
AU3046897A (en) 1998-01-05
ITRM960364A1 (en) 1997-11-28
ITRM960364A0 (en) 1996-05-28
WO1997045127A1 (en) 1997-12-04
EP0914131A1 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
NO20000688D0 (en) Use of locally delivered metal ions for the treatment of periodontal disease
HK1037861A1 (en) Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention
ITRM920412A0 (en) HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE.
ITTO950104A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
DE69620691T2 (en) Therapeutic agent for the treatment of hypercholesterolemia
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
ID23528A (en) THERAPEUTIC TREATMENT FOR SKIN DISORDERS
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
PT900563E (en) PRODUCTION OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF EDEMA AND VENOUS DISEASES
EP0744176A3 (en) Methods for inhibiting bone loss
ITTO950099A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
FR2786100B1 (en) NEW THERAPEUTIC APPLICATION OF NICERGOLIN
NO982562D0 (en) Composition for the treatment of pain
IT240104Y1 (en) DEVICE FOR THE TREATMENT OF THE HUMAN BODY.
GB9615710D0 (en) Pharmaceutical preparations for the treatment of sarcocystosis
GC0000176A (en) Pharmaceutical combination preparations for the treatment of cardiac disorders
ITBO940254A0 (en) METHOD FOR THE IMPROVEMENT OF SOME FUNCTIONS OF THE HUMAN BODY.
FR2786099B1 (en) NEW THERAPEUTIC APPLICATION OF 1,6-DIMETHYL-8BETA- HYDROXYMETHYL-10ALPHA-METHOXYERGOLINE
IT1275604B1 (en) DEVICE FOR THE REDUCTION OF STENOSIS OF ORGANS OF THE HUMAN BODY
ITVR980074A0 (en) PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF SKIN DISEASES.
IT1293464B1 (en) ELECTROMEDICAL DEVICE FOR THE TREATMENT OF ACUTE INFLAMMATORY DISEASES

Legal Events

Date Code Title Description
0001 Granted